公开(公告)号：US20100086522A1

公开(公告)日：2010-04-08

申请号：US12374277

申请日：2007-07-18

申请人： John C. Bell ,  Anthony T. Power

发明人： John C. Bell ,  Anthony T. Power

IPC分类号： A61K35/76 ,  C12N5/00

CPC分类号： A61K35/766 ,  A61K47/6901 ,  A61K2039/515 ,  C12N2760/20232

摘要： The invention provides compositions and methods for treating neoplastic disease, such as cancer, with an oncolytic virus, such as VSV. A carrier cell is used to target a diseased tissue, and to cloak the oncolytic virus from surveillance by the subject's immune system during a targeting interval. Following delivery of the virus to the target tissue, the lysis of the carrier cell, and of the target cell, by the oncolytic virus, promotes an adaptive tumouricidal immune response. A wide variety of disparate carrier cells may be used, in conjunction with a promiscuous oncolytic virus having broad tropism, in an approach which facilitates successive treatments in which a new carrier will not be susceptible to an adaptive immune response mounted against previously used carriers. The promiscuity of the virus also facilitates lysis of carrier cells and target cells that are allogenic or xenogenic. The lytic phase of the carrier cell infection is staged so that the carrier is administered in an eclipse phase, and lysis follows the conclusion of the therapeutic targeting interval.

摘要翻译： 本发明提供了用溶瘤病毒如VSV治疗肿瘤疾病如癌症的组合物和方法。 载体细胞用于靶向患病组织，并且在靶向间隔期间通过受试者的免疫系统对溶瘤病毒进行遮盖。 在将病毒递送至靶组织后，溶瘤病毒对载体细胞和靶细胞的裂解促进适应性的免疫反应。 可以使用多种不同的载体细胞，与具有广泛趋向性的混杂溶瘤病毒联合使用，其有利于连续治疗，其中新载体不会对针对先前使用的载体安装的适应性免疫应答敏感。 病毒的混杂也有助于溶解同种异体或异种的载体细胞和靶细胞。 载体细胞感染的裂解期分期进行，使得载体在日食阶段施用，并且裂解遵循治疗靶向间隔的结论。